Therapeutic area
Immunology & Inflammation biotech companies
The 10 immunology & inflammation companies we cover, with cash and runway from their latest SEC filings, trial milestones from ClinicalTrials.gov, and FDA decisions from their own 8-Ks. Companies are tagged by the areas their pipelines target.
Companies
| Company | Most advanced program | Cash & investments | Runway | Profile |
|---|---|---|---|---|
| REGNRegeneron Pharmaceuticals | Dupixent · multiple type 2 inflammatory diseasesApproved | $17.82B2026-06-30 | — | archived |
| MRNAModerna | mRNA-1345 (RSV) · Respiratory syncytial virus (RSV) in older adultsApproved | $6.91B2026-06-30 | — | archived |
| GILDGilead Sciences | Biktarvy · HIVApproved | $3.18B2026-06-30 | — | archived |
| NTLAIntellia Therapeutics | NTLA-2001 (nexiguran ziclumeran) · Transthyretin amyloidosis (ATTR) — hereditary and wild-typePhase 3 | $628M2026-06-30 | ~19 mo | maintained |
| ABBVAbbVie | Skyrizi · psoriasis, inflammatory bowel disease, and related immunology usesApproved | no filing parsed | — | archived |
| AMGNAmgen | TEPEZZA · thyroid eye diseaseApproved | no filing parsed | — | archived |
| ARGXargenx SE | Vyvgart · Generalized Myasthenia GravisApproved | no filing parsed | — | archived |
| HALOHalozyme Therapeutics | Darzalex Faspro economics exposure · multiple myelomaApproved | no filing parsed | — | archived |
| IMVTImmunovant | Batoclimab · generalized myasthenia gravis and thyroid eye diseasePhase 3 | no filing parsed | — | archived |
| INCYIncyte | Jakafi · myelofibrosis and graft-versus-host diseaseApproved | no filing parsed | — | archived |
Runway is cash divided by quarterly operating burn and is not shown for companies funded by their own revenue. Figures and their dates are on each company page, linked to the filing.
Upcoming trial milestones
- 2027-09 · IMVT · IMVT-1402 RA: IMVT-1402 in ACPA-positive rheumatoid arthritis — primary completion ClinicalTrials.gov
- 2027-09-28 · INCY · AXemplify-357: Axatilimab in Chronic graft-versus-host disease, first line — primary completion ClinicalTrials.gov
- 2028-02-07 · REGN · OLYMPIA-1: Odronextamab in Previously untreated follicular lymphoma — primary completion ClinicalTrials.gov
- 2028-03 · ABBV · Venetoclax ramp-up CLL: Venetoclax in Previously untreated chronic lymphocytic leukaemia — primary completion ClinicalTrials.gov
- 2028-03 · HALO · XYOSTED adolescent: Testosterone enanthate (XYOSTED) in Male adolescent hypogonadism — primary completion ClinicalTrials.gov
- 2028-06 · IMVT · IMVT-1402 Graves: IMVT-1402 in Graves' disease — primary completion ClinicalTrials.gov
- 2028-06-19 · REGN · Dupilumab paediatric EoE: Dupilumab in Eosinophilic oesophagitis in children — primary completion ClinicalTrials.gov
- 2028-11-15 · INCY · INCB123667 ovarian: INCB123667 in Platinum-resistant ovarian cancer, cyclin E1 overexpression — primary completion ClinicalTrials.gov
- 2029-01-04 · AMGN · DeLLphi-312: Tarlatamab in Untreated extensive-stage small-cell lung cancer — primary completion ClinicalTrials.gov
- 2029-01-31 · AMGN · Etelcalcetide paediatric: Etelcalcetide in Secondary hyperparathyroidism on haemodialysis — primary completion ClinicalTrials.gov
- 2029-06-15 · INCY · EXCALIBUR-ET2: INCA033989 in CALR-mutant essential thrombocythemia — primary completion ClinicalTrials.gov
- 2030-01-18 · REGN · Pozelimab + cemdisiran PNH: Pozelimab and cemdisiran in Paroxysmal nocturnal haemoglobinuria — primary completion ClinicalTrials.gov
- 2031-05 · GILD · KITE-753 vs axi-cel: KITE-753 in Relapsed/refractory large B-cell lymphoma — primary completion ClinicalTrials.gov
A registry milestone is the date data collection is scheduled to end, not the date results are released.
FDA decisions
None of these companies has an FDA decision on our PDUFA calendar, which lists only dates a company has stated in a filing.
Educational information, not investment advice. See where each field comes from.